Living with type 1 diabetes (T1D) presents many challenges in terms of daily living. Insulin users need to frequently monitor their blood glucose levels and take multiple injections per day and/or multiple boluses through an insulin infusion pump, with the consequences of failing to match the insulin dose to the body's needs resulting in hypoglycaemia and hyperglycaemia. The former can result in seizures, coma and even death; the latter can have both acute and long-term health implications. Many patients with T1D also fail to meet their treatment goals. In order to reduce the burdens of self-administering insulin, and improve efficacy and safety, there is a need to at least partially remove the patient from the loop via a closed-loop 'artificial pancreas' system. The Hypoglycaemia-Hyperglycaemia Minimizer (HHM) System, comprising a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM) and closed-loop insulin dosing algorithm, is able to predict changes in blood glucose and adjust insulin delivery accordingly to help keep the patient at normal glucose levels. Early clinical data indicate that this system is feasible, effective and safe, and has the potential to dramatically improve the therapeutic outcomes and quality of life for people with T1D.
Type 1 diabetes (T1D) is a lifelong condition that results from autoimmune destruction of insulin-secreting beta cells, resulting in an absence of insulin production. In the US, it is estimated that 29.1 million people have diabetes, 1 with T1D accounting for 5-10% of all cases. Furthermore, its incidence is increasing, particularly among children under the age of 15. 2 A doubling of new cases of T1D in European children younger than five years has been predicted between 2005 and 2020, with a 70% rise in children younger than 15 years. 3 Optimal glycaemic control is essential in people living with T1D; intensive treatment of T1D has been associated with delayed onset and slowed progression of numerous complications, including diabetic retinopathy, nephropathy and neuropathy. 4 Management of T1D involves multiple daily injections of insulin or use of an insulin pump, both of which require the user to actively track glucose and calculate the needed insulin dose. There is also a significant time lag between when a dose is administered and when it takes effect. Other therapies, including immunotherapy and islet cell transplantation, have been investigated, but with limited success. 5, 6 There is therefore a need for an automated system that removes the patient from the loop: a closed-loop system. 7 This article discusses the potential clinical benefits of closed-loop systems, with a focus on the Hypoglycaemia-Hyperglycaemia Minimizer System (HHM System; Animas Corporation, West Chester, PA, US).
The Treatment Burden of Living with Type 1 Diabetes
Exogenous insulin therapy is not subject to the usual physiological feedback mechanisms so may induce hypoglycaemia. 8 The risk of hypoglycaemia limits the efficacy of insulin therapy; the average patient suffers two episodes of symptomatic hypoglycaemia per week and one severe episode per year. 4, [8] [9] [10] Severe hypoglycaemic episodes often occur during sleep.
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These episodes, termed nocturnal hypoglycaemia, can cause convulsions and coma, 12 and can be a rare cause of death in individuals with T1D. 13 The fear of hypoglycaemia has been associated with decreased quality of life in children with T1D 14 and their parents. 15 Fear of hypoglycaemia can also result in avoidance of activities beneficial to health, such as exercise. 16 In addition, insulin therapy is associated with poor compliance. In the US, children with T1D often do not meet their treatment goals in terms of glycated haemoglobin (HbA 1c ) values. 17 Several factors contribute to this failure, including difficulty in correctly estimating the amount of carbohydrates in a meal, missed meal boluses and anxiety about hypoglycaemia resulting in under-treatment. Poor glycaemic control may affect cognitive development in children with T1D. 18 In addition, short-term variation in glucose levels can have an effect on complications of T1D. 19 It is well-known that compliance is difficult to achieve with complicated treatment regimens.
Insulin pump therapy has been associated with improvements in glycaemic control in adults and children with T1D. 20 Continuous subcutaneous insulin infusion (CSII) therapy is conducted using a durable or patch pump that delivers insulin continuously from a cartridge reservoir via a subcutaneously inserted cannula. The pump can be programmed to deliver varied basal rates of insulin throughout the day, with additional boluses of insulin delivered via self-administration at meal times. 22 in adult patients with T1D. CGM has also been associated with benefits in quality of life (QoL), which are correlated with satisfaction with device accuracy and usability and trust in one's ability to use CGM data. 23 Widespread adoption of CGM has been constrained by its cost and limited reimbursement in healthcare schemes, 24 but a growing body of evidence supports its use, 21, 25 resulting in expert opinions that reimbursement is justified in certain patient groups. 26 In order to be used within a closed-loop system, good continuous glucose sensor performance is crucial. However, continuous glucose sensors have been associated with a failure to detect more than half of hypoglycaemic events as well as giving false alarms of impending hypoglycaemia. 27 While standards for accuracy exist (International Organization for Standardization 15197:2013), there is no consensus on a standard method for assessing accuracy. Studies do not always assess CGM across all glycaemic ranges. 27, 28 A comparison of the two most widely used sensor systems, the G4 ® platinum (Dexcom, San Diego, CA, US) and the Paradigm Veo Enlite™ (Medtronic, Northridge, CA, US) found that the G4 sensor was significantly more accurate than the Enlite system, and that both were less accurate in the hypoglycaemic range. 29 In another study the Dexcom G4 sensor showed greater overall accuracy than the Enlite system both overall and for glucose levels in the hypoglycaemic range. In addition, patient satisfaction was higher using the G4 system than the Enlite. 30 A further head-to-head comparison of three CGMs (FreeStyle Navigator, [Abbott Diabetes Care, Alameda, CA, US]; G4 Platinum and Enlite) in adult and paediatric patients with T1D under closed-loop blood glucose control demonstrated that the G4 was the most accurate and precise of the devices studied, followed closely by the Navigator, and both were markedly more accurate and precise than the Enlite sensor. 31 Perhaps the most important benefit of CGM is avoidance of hypoglycaemic events. Hypoglycaemia can also be avoided by aiming for a slightly higher glucose target: a set point of 140 mg/dL could significantly reduce the risk of severe hypoglycaemia with an acceptable increase in time spent at higher glucose range. 32 However, CGM systems have limitations as they still require considerable patient participation in terms of glucose testing, counting carbohydrates and estimating insulin dosages to be administered. This is feasible, if demanding, during the day, but not at night, when many hypoglycaemic episodes occur. There remains a need for control algorithms that adjusts insulin delivery according to daily food intake and activity.
The Concept of a Closed-loop Delivery System
There remains a need to 'close the loop' between the glucose sensor and insulin pump. The aim of such a closed-loop delivery system is to at least partially automate insulin delivery based on CGM so as to obtain improved glucose control. The first closed loop system was developed over 40 years ago. However, this device was used only for academic purposes. 33 Around 20 years ago, large bedside systems using intravenous blood sampling and intravenous insulin infusion became available in intensive care settings in Japan, but their use was infrequent. 34 Transition of such systems to routine clinical use requires accurate, minimally invasive CGM technology integrated with subcutaneous insulin delivery devices -and physiologically informed algorithms to connect the two.
Recent systems use a control algorithm, i.e. software stored on a pump, smartphone or other device, to regulate the insulin delivery based on real-time glucose levels obtained by the sensor. The development of a closed-loop system has faced many difficulties including accuracy of CGM, the physiological time lags involved in the diffusion of the glucose from the plasma to the interstitial fluid when glucose is changing rapidly and delays in both the absorption of insulin and its onset of action after a subcutaneous injection. 7 A number of systems are currently undergoing clinical investigation. A growing body of data indicates that these are safe and feasible in daily living situations and result in improved glycaemic control (see Table 1 ).
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Industry's first foray into commercially available closed-loop technology was the MiniMed ® 530G (Medtronic, Northridge, CA, US).
In brief, the algorithm in such a device uses simple, straightforward logic to suspend insulin delivery when a breach of a low threshold is registered by the integrated CGM, with an associated patient notification. The suspension continues until that confirmation is acknowledged, or when two hours have elapsed, whichever comes first. 44 Such systems have been shown to be effective in improving glycaemic control and reducing hypoglycaemia 45 in patients with T1D. Other clinical development studies sponsored by Medtronic are in progress, investigating more sophisticated algorithms. 46 The predictive low glucose suspend system represents an advance from the glucose suspend device, and halts insulin delivery overnight with the aim of preventing nocturnal hypoglycaemia. [47] [48] [49] Such systems have also been evaluated for use during exercise, with positive results. 50 Studies have found that attitudes towards closed-loop systems are positive among patients 51 and caregivers of children with T1D. 52 Nighttime blood glucose control is the biggest concern for parents and a small study (n=19) indicated that 90% of parents trusted an algorithm to control overnight insulin delivery. the control algorithm, which calculates the optimal amount of insulin to deliver to the patient based on CGM trends, previously infused insulin and model predictions. The algorithm determines how much insulin is needed to result in the optimal glucose trajectory for the near future, and transmits this information to the insulin pump for delivery. This process is repeated every five minutes, each time a new CGM datum is received. This study also evaluated the 'aggressiveness factor', which refers to the speed and magnitude at which the control algorithm adjusts insulin infusion in response to changing CGM measurements (see Figure 4) .
Feasibility Studies Investigating the
Enrolment criteria were current use of an insulin infusion pump with rapid-acting insulin, and a HbA 1c level <10%. Participants were assigned to conservative, medium and aggressive values. Time spent within the normal glycaemic range was highest using the aggressive setting. 54, 55 In a third study, 12 adults with T1D were studied for approximately 24 hours. The purpose of this study was to isolate the hypoglycaemia minimisation aspect of the HHM System. As the aggressiveness setting was increased from 'conservative' to 'medium' to 'aggressive', the 
